These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 12850364)

  • 1. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.
    Piedra PA; Jewell AM; Cron SG; Atmar RL; Glezen WP
    Vaccine; 2003 Jul; 21(24):3479-82. PubMed ID: 12850364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
    Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
    J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze.
    Stensballe LG; Ravn H; Kristensen K; Agerskov K; Meakins T; Aaby P; Simões EA
    J Allergy Clin Immunol; 2009 Feb; 123(2):398-403. PubMed ID: 19101023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus.
    Luchsinger V; Piedra PA; Ruiz M; Zunino E; Martínez MA; Machado C; Fasce R; Ulloa MT; Fink MC; Lara P; Avendaño LF
    Clin Infect Dis; 2012 Apr; 54(7):905-12. PubMed ID: 22238168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease.
    Wang EE; Law BJ; Robinson JL; Dobson S; al Jumaah S; Stephens D; Boucher FD; McDonald J; Mitchell I; MacDonald NE
    Pediatrics; 1997 Mar; 99(3):E9. PubMed ID: 9099774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
    Bonnin FA; Talarico LB; Ferolla FM; Acosta PL; Phung E; Kumar A; Toledano A; Caratozzolo A; Neira P; Mascardi N; Satragno D; Contrini MM; Graham BS; Ruckwardt TJ; López EL;
    Vaccine; 2024 Nov; 42(25):126119. PubMed ID: 39003106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.
    Walsh EE; Wang L; Falsey AR; Qiu X; Corbett A; Holden-Wiltse J; Mariani TJ; Topham DJ; Caserta MT
    J Infect Dis; 2018 Jun; 218(2):208-217. PubMed ID: 29546402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.
    Eick A; Karron R; Shaw J; Thumar B; Reid R; Santosham M; O'Brien KL
    Pediatr Infect Dis J; 2008 Mar; 27(3):207-12. PubMed ID: 18277934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.
    Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Henke DM; Patel KD; Piedra FA; Angelo LS; Shah DP; Chemaly RF; Piedra PA
    Viruses; 2021 May; 13(6):. PubMed ID: 34073490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to respiratory syncytial virus: a population-based cross-sectional serological study in Southern China, 2021.
    Wang Q; Liu N; Wang Y; Ruckwardt TJ; Xu M; Wu J; Zhang J; Tong X; Zhou J; Lin J; Liang Y; Yang J; Yi L; Chu HY; Yu H
    Clin Microbiol Infect; 2024 Sep; 30(9):1183-1189. PubMed ID: 38852851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.
    Jounai N; Yoshioka M; Tozuka M; Inoue K; Oka T; Miyaji K; Ishida K; Kawai N; Ikematsu H; Kawakami C; Shimizu H; Mori M; Ishii KJ; Takeshita F
    EBioMedicine; 2017 Feb; 16():124-135. PubMed ID: 28111238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal.
    Chu HY; Tielsch J; Katz J; Magaret AS; Khatry S; LeClerq SC; Shrestha L; Kuypers J; Steinhoff MC; Englund JA
    J Clin Virol; 2017 Oct; 95():90-95. PubMed ID: 28903080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age.
    Jans J; Wicht O; Widjaja I; Ahout IM; de Groot R; Guichelaar T; Luytjes W; de Jonge MI; de Haan CA; Ferwerda G
    PLoS One; 2017; 12(1):e0170877. PubMed ID: 28135305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.
    Falsey AR; Koval C; DeVincenzo JP; Walsh EE
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28054734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.
    Capella C; Chaiwatpongsakorn S; Gorrell E; Risch ZA; Ye F; Mertz SE; Johnson SM; Moore-Clingenpeel M; Ramilo O; Mejias A; Peeples ME
    J Infect Dis; 2017 Dec; 216(11):1398-1406. PubMed ID: 29029312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of serum neutralizing antibody in reinfection of respiratory syncytial virus.
    Kawasaki Y; Hosoya M; Katayose M; Suzuki H
    Pediatr Int; 2004 Apr; 46(2):126-9. PubMed ID: 15056236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants.
    Koivisto K; Nieminen T; Mejias A; Capella Gonzalez C; Ye F; Mertz S; Peeples M; Ramilo O; Saxén H
    J Infect Dis; 2022 Apr; 225(7):1189-1196. PubMed ID: 34129040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of complement in neutralization of respiratory syncytial virus.
    Yoder SM; Zhu Y; Ikizler MR; Wright PF
    J Med Virol; 2004 Apr; 72(4):688-94. PubMed ID: 14981775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.